May 3, 2016


Barbara Netter, Honorary Chairman and Co-Founder pictured with John Walter, ACGT CEO and President.
John Walter joined ACGT in April as CEO and President, succeeding Co-Founder Barbara Netter who will continue her leadership role as Honorary Chairman of the Board of Directors. John is the former CEO of the Leukemia and Lymphoma Society where he served in several different positions and dramatically expanded research collaborations with biotech and academia. He is also credited with spearheading revenue growth to $320 million annually. Previously he served with the March of Dimes and with Donaldson, Lufkin & Jenrette and Bristol-Myers Squibb. "The time has come to capitalize on the organization's momentum with new leadership," Mrs. Netter announced at the recent Scientific Symposium. ACGT has established a prestigious and vital organization in just the fifteen years since Mrs. Netter and her late husband Edward founded the philanthropy, which is still the only non-profit in the nation focused solely on cell and gene therapy research for cancer. To-date, 50 grants, totaling $26 million, have been awarded to prestigious clinical researchers in North America at a time when innovative research desperately needs funding to move the science more rapidly to medical practice. Read more.


You may never realize how critical medical research is until you discover you, or a loved one, has cancer. Although the reward may not seem immediate, research is the key to saving lives. Celebrate the moms you love - your mother, your grandmother, your children's mother - by making a donation to Alliance for Cancer Gene Therapy and help end cancer soon enough to save the people you love. Give Now             


At the ACGT Scientific Symposium April 14th in NYC, 27 cancer researchers joined members of  ACGT's Board of Directors to share status and zero in on the challenges of cell and gene therapies. All agreed that research is rapidly breaking through barriers to better treatment. Several FDA approved drugs are now available to stimulate the immune system to wage war on melanoma, lung and breast cancers, and remarkable success has been achieved with leukemia and lymphoma. While few therapies are yet capable of eradicating cancer on their own, lives have been extended in combination with traditional treatments. Every day, in clinical trials across the country, cancer patients facing end-of-life prognoses are able to extend survival rates or realize long-term remission. The challenge is to zero in on the dosages, sequence, delivery systems and the best possible combinations of treatment for each individual cancer and ultimately for each individual patient.
"Scientists strive to better comprehend the tumor environment and there is a greater understanding of immunotherapy and antibodies now which hold the key to killing cancer."
Barbara Netter, Honorary Chairman of the Board of Directors and Co-Founder, ACGT
Our new Board director, Chau Q. Khuon g, is a partner in the private equity group at OrbiMed Advisors, a global health care investment firm with approximately $15 billion under management. He has been an active lead investor in innovative drug development and medical device enterprises and also serves on the Boards of several private and public companies. Chau earned a BS in molecular, cellular and developmental biology, with a concentration in biotechnology, and an MPH with a focus on infectious diseases, at Yale University.
Join us Saturday, June 25

Dip into the Long Island Sound or a local pool, or boat across the waters from Greenwich to Stamford, CT, Saturday morning June 25th to contribute to private funding for cutting-edge research to beat cancer. A 10-year tradition, Swim Across America has raised almost $3 million for ACGT and the event is a unique way to pay tribute to a loved one or survivor, or honor cancer patients fighting for their lives. Chaired once again by Michele Graham and Lorrie Lorenz, both mothers of cancer survivors, the morning promises a good time for a good cause. Join us in making waves to fight cancer as a swimmer, boater or land volunteer.
"The ACGT Swim Across America grant was the first major grant I received as a Principal Investigator, which was instrumental in jump- starting my research career by allowing my laboratory to obtain key data sets to ultimately secure funding by NIH and other agencies."
Dr. Khalid Shah, Harvard Medical School, Massachusetts General Hospital
The first ACGT - Wendy Walk Sarcoma grant has been awarded to Dr. Crystal Mackall, Professor of Pediatrics and Internal Medicine at Stanford University. The $500,000 partnership grant supports research leading to clinical trial to treat osteosarcoma, an especially lethal bone cancer that attacks children. Currently the odds of survival are just 50%. Wendy Walk is a non-profit founded in 2010 by the three children of Wendy Landes, who succumbed to a rare form of the disease. Wendy Walk sponsors events in NYC, Miami, Los Angeles and Park City and has raised to-date $2.25 million. Dr. Mackall's immunology research uses engineered T-cells to target and destroy the cancer. She received her MD from Northeastern Ohio University College of Medicine and served a fellowship in pediatric hematology/oncology and a post-doctoral fellowship at the National Cancer Institute. Read more.

ACGT is the only non-profit organization in the nation dedicated exclusively to funding  cell and gene therapies for cancer. Since its founding in 2001, ACGT has awarded  50 gr ants of over $26 million in North America, and continues to be a catalyst for cell and gene therapy research.
100% of all donations are used to support ACGT research grants and studies in cell and gene therapies for cancer.

Share our hope and share our dedication to more effective ways of targeting cancer .
Please forward this email to anyone whose life has been touched by cancer. 
Keep posted on progress at, on Facebook and Twitter.